Statin Inhibits TGF-β1-induced Epithelial-Mesenchymal Transition in Lung Cancer Cell Line
분야
의약학 > 내과학
저자
김서윤 , 이진우 , 이창훈 , 이상민 , 임재준 , 유철규 , 김영환 , 한성구 , 박영식
발행기관
대한결핵 및 호흡기학회
간행물정보
대한결핵및호흡기학회 추계학술발표초록집 2012년, 제114권 295(총1페이지)
파일형식
0y910087.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    1,000원
    적립금
    30원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    영문초록
    Purpose: Statins, HMG-CoA reductase inhibitors have been shown to inhibit Rho-GTPase signaling, intracellluar signaling molecules involved in epithelial-mesenchymal transition (EMT). Therefore, we investigated whether pravastatin inhibited transforming growth factor (TGF)-β1-induced epithelial-mesenchymal transition in lung cancer cell line. Methods: Cultured adenocarcinomic human alveolar basal epithelial cells (A549 cells) were pretreated with or without 10 uM pravastatin for 24 hours and then were stimulated with TGF-β1, 5 ng/ml for 36 hours. The effect of pravastatin on ex-pression of epithelial phenotypic markers, E-cadherin and mesenchymal phenotypic markers, vimentin was determined by Western blot. Results: Our study confirmed that TGF-β1 induced EMT of A549 cells characterized by cells morphological changes and decrease of expression of E-cadherin, concomitant with increase of vimentin. Inhibition of EMT in A549 cells with pravastatin resulted in preservation of the expression of E-cadherin and in a decrease in vimentin expression. Conclusion: This study shows that pravastatin inhibits the TGF-β-induced EMT of cultured A549 cells. Further studies are needed to elucidate signaling pathway of statins in inhibiting EMT.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일 help@reportshop.co.kr
    copyright (c) 2009 happynlife. steel All reserved.